Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone Sustained-Release for Autonomic Dysfunction with Vertigo
NCT05430217Phase 3Completed
- Sponsor
- Valenta Pharm
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buspirone in autonomic nervous system disorder, vertigo, sponsored by Valenta Pharm. Started Jan 2022; status: completed.
02
Drugs
buspirone
03
Conditions
autonomic nervous system disordervertigo
Beyond the preview
Go deeper on NCT05430217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430217.